These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2826829)

  • 21. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies.
    Hellriegel ET; Bjornsson TD; Hauck WW
    Clin Pharmacol Ther; 1996 Dec; 60(6):601-7. PubMed ID: 8988062
    [No Abstract]   [Full Text] [Related]  

  • 22. Dilemma with matrix effect in bioanalysis--perspectives from bioavailability/bioequivalence studies for product registration?
    Srinivas NR
    Drug Res (Stuttg); 2014 Jun; 64(6):335-6. PubMed ID: 24258702
    [No Abstract]   [Full Text] [Related]  

  • 23. The pharmacokinetics and efficacy of different estrogens are not equivalent.
    Ansbacher R
    Am J Obstet Gynecol; 2001 Feb; 184(3):255-63. PubMed ID: 11228470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Society testifies on bioavailability, bioequivalence.
    Hayes AH
    Pa Med; 1975 Sep; 78(9):59-60. PubMed ID: 1178207
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical relevance of the bioavailability/bioequivalence controversy.
    Gottschalk LA
    J Clin Psychiatry; 1986 Sep; 47 Suppl():3-5. PubMed ID: 3528133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 27. Branded versus generic clozapine: bioavailability comparison and interchangeability issues.
    Lam YW; Ereshefsky L; Toney GB; Gonzales C
    J Clin Psychiatry; 2001; 62 Suppl 5():18-22; discussion 23-4. PubMed ID: 11305844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative approach to relative bioavailability and bioequivalence evaluation, with drugs following Michaelis-Menten elimination kinetics.
    Fagiolino P; Stareczek S
    Farmaco; 1990 Sep; 45(9):1027-36. PubMed ID: 2282123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability/bioequivalence: study design and statistical issues.
    Metzler CM
    J Clin Pharmacol; 1989 Apr; 29(4):289-92. PubMed ID: 2656773
    [No Abstract]   [Full Text] [Related]  

  • 30. Harmonization of bioavailability and bioequivalence requirements.
    McGilveray IJ; Ormsby E
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():533-40. PubMed ID: 1820935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Status of generic substitution: problematic drug classes reviewed.
    Ross MB
    Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New guidelines for the assessment of bioavailability and bioequivalence].
    Blume H; Schug B; Tautz J; Erb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the bioequivalence and bioavailability of three coenzyme Q10 products.
    Chopra RK; Bhagavan HN
    J Med Food; 2006; 9(1):131-2; author reply 133-4. PubMed ID: 16579742
    [No Abstract]   [Full Text] [Related]  

  • 35. What makes a generic medication generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
    Ereshefsky L; Jann MW; Saklad SR; Davis CM
    J Clin Psychiatry; 1986 Sep; 47 Suppl():6-15. PubMed ID: 3528134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "One-size-fits-all" in bioavailability and bioequivalence testing?
    Blume HH
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):419-20. PubMed ID: 19640347
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioequivalence and intrasubject variability.
    Liu JP
    J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling and simulation of biopharmaceutical performance.
    Zhang X; Lionberger RA
    Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1992; 14(6):469-82. PubMed ID: 1469957
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.